Clinical Inertia in Type 2 Diabetes: A Retrospective Analysis of Pharmacist-managed Diabetes Care Vs. Usual Medical Care

Overview

Journal Pharm Pract (Granada)

Date 2013 Dec 25

PMID 24367460

Citations 11

Authors

Felix K Yam

Aimee G Adams

Holly Divine

Douglas Steinke

Mikael D Jones

Affiliations

Soon will be listed here.

Abstract

Background: Evidence suggests that patients with type 2 diabetes (T2DM) suffer from a high rate of "clinical inertia" or "recognition of the problem but failure to act."

Objective: THE AIM OF THIS STUDY IS TO QUANTIFY THE RATE OF CLINICAL INERTIA BETWEEN TWO MODELS OF CARE: Pharmacist-Managed Diabetes Clinic (PMDC) vs. Usual Medical Care (UMC).

Methods: Patients in a university based medical clinic with type 2 diabetes (T2DM) were analyzed in this retrospective cohort study. Patients were exposed to either PMDC or UMC. The difference in days to intervention in response to suboptimal laboratory values and time to achieve goal hemoglobin A1c (A1c), systolic blood pressure (SBP) and low-density lipoprotein (LDL) was compared in the two models of care.

Results: A total of 113 patients were included in the analysis of this study, 54 patients were in the PMDC and 59 patients were in the UMC group. Median time (days) to intervention for A1c values >7% was 8 days and 9 days in the PMDC and UMC groups, respectively (p>0.05). In patients with baseline A1c values >8%, median time to achieving A1c<7% was 259 days vs. 403 days in the PMDC and UMC groups, respectively (p<0.05). Median time to goal SBP was 124 days in the PMDC group and 532 days in the UMC group (p<0.05). Median time to goal LDL was 412 days in the PMDC group vs. 506 days in the UMC group (p<0.05).

Conclusions: Rates of clinical inertia, defined as time to intervention of suboptimal clinical values, did not differ significantly between patients enrolled in a PMDC compared to patients with UMC with respect to A1c, SBP and LDL. Participation in PMDC, however, was associated with achieving goal A1c, SBP, and LDL levels sooner compared to UMC.

Citing Articles

Clinician challenges to evidence-based prescribing for heart failure and reduced ejection fraction: A qualitative evaluation.

Trinkley K, Dafoe A, Malone D, Allen L, Huebschmann A, Khazanie P J Eval Clin Pract. 2023; 29(8):1363-1371.

PMID: 37335624 PMC: 11075805. DOI: 10.1111/jep.13885.

Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A Systematic Review.

Almigbal T, Alzarah S, Aljanoubi F, Alhafez N, Aldawsari M, Alghadeer Z Medicina (Kaunas). 2023; 59(1).

PMID: 36676805 PMC: 9866102. DOI: 10.3390/medicina59010182.

Liu Wei Di Huang Wan and the Delay of Insulin Use in Patients with Type 2 Diabetes in Taiwan: A Nationwide Study.

Chen H, Wu C, Tsai Y, Ho C, Hsieh M, Lai J Evid Based Complement Alternat Med. 2021; 2021:1298487.

PMID: 34457016 PMC: 8390129. DOI: 10.1155/2021/1298487.

Combination of disease duration-to-age at diagnosis and hemoglobin A1c-to-serum C-peptide reactivity ratios predicts patient response to glucose-lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59).

Kanatsuka A, Sato Y, Higashi Y, Goto Y, Kawai K, Maegawa H J Diabetes Investig. 2021; 12(11):1967-1977.

PMID: 33837666 PMC: 8565405. DOI: 10.1111/jdi.13558.

Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review.

Andreozzi F, Candido R, Corrao S, Fornengo R, Giancaterini A, Ponzani P Diabetol Metab Syndr. 2020; 12:52.

PMID: 32565924 PMC: 7301473. DOI: 10.1186/s13098-020-00559-7.

References

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Divine H, Nicholas A, Johnson C, Perrier D, Steinke D, Blumenschein K . PharmacistCARE: description of a pharmacist care service and lessons learned along the way. J Am Pharm Assoc (2003). 2008; 48(6):793-802. DOI: 10.1331/JAPhA.2008.07132. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Bodenheimer T, Wagner E, Grumbach K . Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA. 2002; 288(15):1909-14. DOI: 10.1001/jama.288.15.1909. View

. Standards of medical care in diabetes. Diabetes Care. 2004; 28 Suppl 1:S4-S36. View

Zellmer W, Cobaugh D, Chen D . Three signals from the Pharmacy Practice Model Summit. Am J Health Syst Pharm. 2011; 68(12):1077. DOI: 10.2146/ajhp110148. View

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View

Greenfield S, Billimek J, Pellegrini F, Franciosi M, De Berardis G, Nicolucci A . Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med. 2009; 151(12):854-60. DOI: 10.7326/0003-4819-151-12-200912150-00005. View

Johnson C, Nicholas A, Divine H, Perrier D, Blumenschein K, Steinke D . Outcomes from DiabetesCARE: a pharmacist-provided diabetes management service. J Am Pharm Assoc (2003). 2008; 48(6):722-30. DOI: 10.1331/JAPhA.2008.07133. View

10.

DeName B, Divine H, Nicholas A, Steinke D, Johnson C . Identification of medication-related problems and health care provider acceptance of pharmacist recommendations in the DiabetesCARE program. J Am Pharm Assoc (2003). 2008; 48(6):731-6. DOI: 10.1331/JAPhA.2008.07070. View

11.

Cranor C, Bunting B, Christensen D . The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003; 43(2):173-84. DOI: 10.1331/108658003321480713. View

12.

Shah B, Hux J, Laupacis A, Zinman B, van Walraven C . Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?. Diabetes Care. 2005; 28(3):600-6. DOI: 10.2337/diacare.28.3.600. View

13.

Rodbard H, Blonde L, Braithwaite S, Brett E, Cobin R, Handelsman Y . American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007; 13 Suppl 1:1-68. DOI: 10.4158/EP.13.S1.1. View

14.

Norris S, Engelgau M, Narayan K . Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care. 2001; 24(3):561-87. DOI: 10.2337/diacare.24.3.561. View

15.

Cranor C, Christensen D . The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003; 43(2):149-59. DOI: 10.1331/108658003321480696. View

16.

Grant R, Buse J, Meigs J . Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005; 28(2):337-442. PMC: 3829636. DOI: 10.2337/diacare.28.2.337. View

17.

Phillips L, Branch W, COOK C, Doyle J, Gallina D, Miller C . Clinical inertia. Ann Intern Med. 2001; 135(9):825-34. DOI: 10.7326/0003-4819-135-9-200111060-00012. View

18.

. Standards of medical care in diabetes--2013. Diabetes Care. 2012; 36 Suppl 1:S11-66. PMC: 3537269. DOI: 10.2337/dc13-S011. View